Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony Letai

Showing results (111-120 of 182) with videos related to

Pageof 19
Sort By:
Blood Advances|May 5, 2021
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaStephan R Bohl, Laura K Schmalbrock, Imke Bauhuf, et al.
Nature Communications|October 26, 2017
BCL-X<sub>L</sub> directly modulates RAS signalling to favour cancer cell stemnessSophie de Carné Trécesson, Frédérique Souazé, Agnès Basseville, et al.
American Journal of Hematology|December 6, 2019
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapyJacqueline S Garcia, Shruti Bhatt, Geoffrey Fell, et al.
Science Translational Medicine|December 15, 2017
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosisDavid Lagares, Alba Santos, Paula E Grasberger, et al.
Blood|December 1, 2018
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasRaphael Koch, Amanda L Christie, Jennifer L Crombie, et al.
Leukemia|April 12, 2022
JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemiaKimberly Bodaar, Natsuko Yamagata, Anais Barthe, et al.
Elife|November 21, 2022
Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunctionJacob M Winter, Heidi L Fresenius, Corey N Cunningham, et al.
Cancer Cell|November 16, 2005
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibDharminder Chauhan, Laurence Catley, Guilan Li, et al.
The EMBO Journal|September 15, 2021
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1αDiego A Rodriguez, Sebastian Zamorano, Fernanda Lisbona, et al.
Blood|June 30, 2018
<i>PPM1D</i>-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cellsJosephine D Kahn, Peter G Miller, Alexander J Silver, et al.
Pageof 19

Showing results (111-120 of 182) with videos related to

Sort By:
Pageof 19
Blood Advances|May 5, 2021
Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myelomaStephan R Bohl, Laura K Schmalbrock, Imke Bauhuf, et al.
Nature Communications|October 26, 2017
BCL-X<sub>L</sub> directly modulates RAS signalling to favour cancer cell stemnessSophie de Carné Trécesson, Frédérique Souazé, Agnès Basseville, et al.
American Journal of Hematology|December 6, 2019
Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapyJacqueline S Garcia, Shruti Bhatt, Geoffrey Fell, et al.
Science Translational Medicine|December 15, 2017
Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosisDavid Lagares, Alba Santos, Paula E Grasberger, et al.
Blood|December 1, 2018
Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomasRaphael Koch, Amanda L Christie, Jennifer L Crombie, et al.
Leukemia|April 12, 2022
JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemiaKimberly Bodaar, Natsuko Yamagata, Anais Barthe, et al.
Elife|November 21, 2022
Collateral deletion of the mitochondrial AAA+ ATPase ATAD1 sensitizes cancer cells to proteasome dysfunctionJacob M Winter, Heidi L Fresenius, Corey N Cunningham, et al.
Cancer Cell|November 16, 2005
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from BortezomibDharminder Chauhan, Laurence Catley, Guilan Li, et al.
The EMBO Journal|September 15, 2021
BH3-only proteins are part of a regulatory network that control the sustained signalling of the unfolded protein response sensor IRE1αDiego A Rodriguez, Sebastian Zamorano, Fernanda Lisbona, et al.
Blood|June 30, 2018
<i>PPM1D</i>-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cellsJosephine D Kahn, Peter G Miller, Alexander J Silver, et al.
Pageof 19